CELG News Alert Celgene Corp (CELG) 117.00 01/12/2015 16:00:
Post# of 64205
Posted On: 01/12/2015 5:00:04 PM
Celgene Corp (CELG) 117.00 $CELG
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Mon Jan 12, 12:51PM CST
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
CELG: 117.00 (+3.33)
Comeback Efforts Slow For Stocks; Celgene Gains
at Investor's Business Daily - Mon Jan 12, 12:27PM CST
Stocks were still in the red Monday afternoon as rebound efforts slowed. The Nasdaq and the S&P 500 were off by 0.7% each, while the Dow Jones industrial average fell 0.5%. Volume was again tracking higher on both major exchanges in the stock market...
MU: 31.66 (-1.87), ARUN: 16.93 (-0.80), TIF: 89.01 (-14.44), SNDK: 83.57 (-13.47), CELG: 117.00 (+3.33)
Midday Glance: Biotechnology companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Celgene Says Q4 Earnings Beat, Sees Currency Impact
at Investor's Business Daily - Mon Jan 12, 12:12PM CST
Big cap biotech Celgene (CELG) provided a preliminary fourth-quarter earnings report Monday that topped estimates but warned of foreign exchange currency impacts for the year ahead. Results were presented prior to its presentation early Monday at the...
AGN: 219.58 (+4.18), VRX: 155.50 (+1.92), ACT: 272.28 (+3.60), CELG: 117.00 (+3.33)
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector
Cerebro1 - at Seeking Alpha - Mon Jan 12, 11:10AM CST
AGN: 219.58 (+4.18), VRTX: 118.31 (-3.90), ACT: 272.28 (+3.60), XLV: 70.24 (+0.03), CELG: 117.00 (+3.33)
Celgene reports preliminary results and 2015 outlook
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 10:48AM CST
CELG: 117.00 (+3.33)
Celgene Has 2020 Vision For Long Term Growth But Plays Safe for 2017
at The Street - Mon Jan 12, 10:40AM CST
Celgene CELG CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
CELG: 117.00 (+3.33)
Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results
Business Wire - Mon Jan 12, 9:58AM CST
--Preliminary 2014 Financial Results Including Net Product Sales and Diluted EPS
CELG: 117.00 (+3.33), CELGZ: 3.41 (+0.13)
Early Glance: Biotechnology companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Which Big Biotech Will Soar in 2015?
Motley Fool Staff - Motley Fool - Mon Jan 12, 7:59AM CST
In a bid to help investors identify the biotech companies that could be top stocks this year, we asked three top Motley Fool contributors to tell us which biotech stocks they think could head significantly higher in 2015. Read on to learn which...
BIIB: 347.84 (+5.50), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ABBV: 65.76 (-0.02), CELG: 117.00 (+3.33)
Is Celgene Corporation a Takeover Target in 2015?
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 6:30AM CST
Source: Celgene. The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and an innovation boom that has made...
BLUE: 101.95 (-1.68), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.39 (+0.90), AZN: 70.79 (+1.35), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33), FPRX: 28.00 (+3.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.35 (+3.44), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33), EXEL: 1.65 (-0.11)
An Assorted List Of Mojo, Catalyst, Overhang And Contrarian Stocks For 2015
Ray Merola - at Seeking Alpha - Sat Jan 10, 7:57AM CST
T: 33.49 (+0.09), NUE: 46.00 (-1.78), IP: 53.21 (+0.15), GLD: 118.56 (+1.30), GM: 35.84 (+0.25), BAC: 16.68 (-0.30), INTC: 36.60 (-0.16), AFL: 58.29 (-0.34), CELG: 117.00 (+3.33)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Final Glance: Biotechnology companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
at The Street - Fri Jan 09, 1:56PM CST
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), JUNO: 61.51 (+7.24), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Mon Jan 12, 12:51PM CST
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
CELG: 117.00 (+3.33)
Comeback Efforts Slow For Stocks; Celgene Gains
at Investor's Business Daily - Mon Jan 12, 12:27PM CST
Stocks were still in the red Monday afternoon as rebound efforts slowed. The Nasdaq and the S&P 500 were off by 0.7% each, while the Dow Jones industrial average fell 0.5%. Volume was again tracking higher on both major exchanges in the stock market...
MU: 31.66 (-1.87), ARUN: 16.93 (-0.80), TIF: 89.01 (-14.44), SNDK: 83.57 (-13.47), CELG: 117.00 (+3.33)
Midday Glance: Biotechnology companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Celgene Says Q4 Earnings Beat, Sees Currency Impact
at Investor's Business Daily - Mon Jan 12, 12:12PM CST
Big cap biotech Celgene (CELG) provided a preliminary fourth-quarter earnings report Monday that topped estimates but warned of foreign exchange currency impacts for the year ahead. Results were presented prior to its presentation early Monday at the...
AGN: 219.58 (+4.18), VRX: 155.50 (+1.92), ACT: 272.28 (+3.60), CELG: 117.00 (+3.33)
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector
Cerebro1 - at Seeking Alpha - Mon Jan 12, 11:10AM CST
AGN: 219.58 (+4.18), VRTX: 118.31 (-3.90), ACT: 272.28 (+3.60), XLV: 70.24 (+0.03), CELG: 117.00 (+3.33)
Celgene reports preliminary results and 2015 outlook
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 10:48AM CST
CELG: 117.00 (+3.33)
Celgene Has 2020 Vision For Long Term Growth But Plays Safe for 2017
at The Street - Mon Jan 12, 10:40AM CST
Celgene CELG CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
CELG: 117.00 (+3.33)
Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results
Business Wire - Mon Jan 12, 9:58AM CST
--Preliminary 2014 Financial Results Including Net Product Sales and Diluted EPS
CELG: 117.00 (+3.33), CELGZ: 3.41 (+0.13)
Early Glance: Biotechnology companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
Which Big Biotech Will Soar in 2015?
Motley Fool Staff - Motley Fool - Mon Jan 12, 7:59AM CST
In a bid to help investors identify the biotech companies that could be top stocks this year, we asked three top Motley Fool contributors to tell us which biotech stocks they think could head significantly higher in 2015. Read on to learn which...
BIIB: 347.84 (+5.50), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ABBV: 65.76 (-0.02), CELG: 117.00 (+3.33)
Is Celgene Corporation a Takeover Target in 2015?
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 6:30AM CST
Source: Celgene. The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and an innovation boom that has made...
BLUE: 101.95 (-1.68), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.39 (+0.90), AZN: 70.79 (+1.35), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33), FPRX: 28.00 (+3.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.35 (+3.44), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33), EXEL: 1.65 (-0.11)
An Assorted List Of Mojo, Catalyst, Overhang And Contrarian Stocks For 2015
Ray Merola - at Seeking Alpha - Sat Jan 10, 7:57AM CST
T: 33.49 (+0.09), NUE: 46.00 (-1.78), IP: 53.21 (+0.15), GLD: 118.56 (+1.30), GM: 35.84 (+0.25), BAC: 16.68 (-0.30), INTC: 36.60 (-0.16), AFL: 58.29 (-0.34), CELG: 117.00 (+3.33)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Final Glance: Biotechnology companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), CELG: 117.00 (+3.33)
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
at The Street - Fri Jan 09, 1:56PM CST
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), JUNO: 61.51 (+7.24), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
(0)
(0)